Charles Schwab Investment Management Inc Lipocine Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022
BUY
$0.99 - $1.2 $49,500 - $60,000
50,000 New
50,000 $50,000
Q3 2021

Nov 16, 2021
SELL
$1.08 - $1.49 $39,522 - $54,526
-36,595 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$1.38 - $2.28 $50,501 - $83,436
36,595 New
36,595 $56,000

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $431M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email